Cytosorbents (CTSO) Depreciation & Amortization (CF) (2010 - 2026)
Cytosorbents (CTSO) posted Depreciation & Amortization (CF) of $300000.0 for Q1 2026, up 209.28% on a QoQ basis from $97000.0 in Q4 2025, and down 18.59% year-over-year from $368503.0 in Q1 2025.
Cytosorbents (CTSO) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Cytosorbents' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $300000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 18.59% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$371000.0 (down 41.88% YoY) and the FY2025 annual result came in at $1.2 million, down 7.57% from the prior year.
- Depreciation & Amortization (CF) was $300000.0 for Q1 2026 at Cytosorbents, up from $97000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $407208.0 in Q3 2023 and bottomed at -$404000.0 in Q2 2025.
- A 5-year average of $123910.4 and a median of $223214.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 91.11% — and 2024, when it slumped 199.76%.
- Cytosorbents' Depreciation & Amortization (CF) stood at $223214.0 in 2022, then jumped by 75.29% to $391269.0 in 2023, then slumped by 60.64% to $154000.0 in 2024, then slumped by 37.01% to $97000.0 in 2025, then soared by 209.28% to $300000.0 in 2026.
- Business Quant data shows CTSO's Depreciation & Amortization (CF) at $300000.0 in Q1 2026, $97000.0 in Q4 2025, and -$364000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 381.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 120.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 716.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 351.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 40.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 67.10 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 310.25 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 78.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | -364,000.00 |
| Sep 30, 2025 | -364,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Mar 31, 2025 | 368,503.00 |
| Mar 31, 2025 | 368,503.00 |
| Dec 31, 2024 | 154,000.00 |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | -383,000.00 |
| Sep 30, 2024 | -383,000.00 |
| Jun 30, 2024 | -401,000.00 |
| Jun 30, 2024 | -401,000.00 |
| Mar 31, 2024 | 397,286.00 |
| Mar 31, 2024 | 397,286.00 |
| Dec 31, 2023 | 391,269.00 |
| Dec 31, 2023 | 391,269.00 |